TRPV1 and atopic eczema: Currently, only two TRPV1 antagonists have been reported to enter Phase III trials for atopic dermatitis (PAC-14,028) and dry eye syndrome (SYL-1001) [105] Hopefully, future clinical studies with TRPV1 receptor antagonists provide an answer as to the role of TRPV1 in inflammatory and neuropathic pain syndromes.